TY - JOUR
T1 - Treatment of spinocerebellar ataxia with buspirone
AU - Assadi, Mitra
AU - Campellone, Joseph V.
AU - Janson, Christopher G.
AU - Veloski, J. Jon
AU - Schwartzman, Robert J.
AU - Leone, Paola
PY - 2007/9/15
Y1 - 2007/9/15
N2 - Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.
AB - Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.
KW - Ataxia
KW - Buspirone
KW - SCA
UR - http://www.scopus.com/inward/record.url?scp=34547683197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547683197&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2007.04.019
DO - 10.1016/j.jns.2007.04.019
M3 - Article
C2 - 17512011
AN - SCOPUS:34547683197
SN - 0022-510X
VL - 260
SP - 143
EP - 146
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
IS - 1-2
ER -